{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:49:40Z","timestamp":1792680580315,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373648"],"award-info":[{"award-number":["82373648"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.eclinm.2025.103177","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T13:37:08Z","timestamp":1742650628000},"page":"103177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effectiveness of tuberculosis preventive treatment in patients with rheumatic diseases: a global systematic review and meta-analysis"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2771-5591","authenticated-orcid":false,"given":"Beiming","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1084-4616","authenticated-orcid":false,"given":"Lifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.eclinm.2025.103177_bib1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1513\/AnnalsATS.201509-632PS","article-title":"Treatment of tuberculosis. A historical perspective","volume":"12","author":"Murray","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103177_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib3","first-page":"541","article-title":"The impact of different rheumatic diseases on health-related quality of life: a comparison with a selected sample of healthy individuals using SF-36 questionnaire, EQ-5D and SF-6D utility values","volume":"89","author":"Salaffi","year":"2019","journal-title":"Acta Biomed"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105364","article-title":"Trained immunity and inflammation in rheumatic diseases","volume":"89","author":"Badii","year":"2022","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.eclinm.2025.103177_bib5","series-title":"Conventional disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis","author":"Hill","year":"2021"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103177_bib6","first-page":"1179","article-title":"Latent Mycobacterium tuberculosis infection","volume":"373","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2025.103177_bib7","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijid.2022.02.047","article-title":"The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection","volume":"124","author":"Goletti","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103177_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224963","article-title":"A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment","volume":"14","author":"Sartori","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103177_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5152\/TurkArchPediatr.2024.23221","article-title":"How safe are biological agents in pediatric rheumatology?","volume":"59","author":"Nur Sunar Yayla","year":"2024","journal-title":"Turk Arch Pediatr"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103177_bib10","doi-asserted-by":"crossref","DOI":"10.1590\/1806-3713\/e20190023","article-title":"Latent tuberculosis infection in patients with rheumatic diseases","volume":"45","author":"Anton","year":"2019","journal-title":"J Bras Pneumol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103177_bib11","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1080\/22221751.2021.2004864","article-title":"Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China","volume":"10","author":"Liu","year":"2021","journal-title":"Emerg Microbes Infect"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103177_bib12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103177_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14740338.2019.1612872","article-title":"Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice","volume":"18","author":"Cantini","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.eclinm.2025.103177_bib14","series-title":"WHO consolidated guidelines on tuberculosis: module 1: prevention - Tuberculosis preventive treatment","year":"2024"},{"key":"10.1016\/j.eclinm.2025.103177_bib15","series-title":"Global tuberculosis report 2024","year":"2024"},{"key":"10.1016\/j.eclinm.2025.103177_bib16","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2025.103177_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103177_bib18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.eclinm.2025.103177_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"SUPPL 1","key":"10.1016\/j.eclinm.2025.103177_bib20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/annrheumdis-2021-eular.1617","article-title":"Effectiveness of screening in patients with rheumatic disease on biological therapy and risk of active tuberculosis","volume":"80","author":"Abdulaziz","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103177_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.5588\/ijtld.15.0283","article-title":"Risk of developing active tuberculosis in rheumatoid arthritis patients on adalimumab in Japan","volume":"20","author":"Watanabe","year":"2016","journal-title":"Int J Tubercul Lung Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103177_bib22","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/rheumatology\/keaa702","article-title":"Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden","volume":"60","author":"Shin","year":"2021","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10067-014-2536-z","article-title":"The use of TNF-\u03b1 blockers in psoriatic arthritis patients with latent tuberculosis infection","volume":"33","author":"Atteno","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103177_bib24","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/rheumatology\/kead315","article-title":"Prevalence of LTBI in patients with autoimmune diseases and accuracy of IGRA in predicting TB relapse","volume":"62","author":"Chandrashekara","year":"2023","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103177_bib25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.23705","article-title":"Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy","volume":"59","author":"Chen","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103177_bib26","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00296-011-2017-5","article-title":"Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients","volume":"32","author":"Nobre","year":"2012","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib27","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s13555-024-01130-2","article-title":"Interleukin-17A inhibitors in patients with psoriasis and tuberculosis infection: a 2-year prospective study on safety without preventive treatment","volume":"14","author":"He","year":"2024","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.eclinm.2025.103177_bib28","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/annrheumdis-2023-eular.1847","article-title":"Analysis of the differences between tuberculosis prophylaxis regimens in biologic candidate patients","volume":"82","author":"Diaz","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103177_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejr.2024.11.003","article-title":"Screening potential of tuberculin skin and interferon gamma release tests for latent tuberculosis prior to anti-tumor necrosis factor (TNF)-\u03b1 therapy in patients with rheumatoid arthritis and spondyloarthritis","volume":"47","author":"Yilmaz","year":"2025","journal-title":"Egypt Rheumatol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103177_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/ajd.14340","article-title":"Evaluation of serial QuantiFERON-TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti-IL-17 treatment (secukinumab and ixekizumab): real-world data from a tuberculosis-endemic country","volume":"65","author":"Erba\u011fc\u0131","year":"2024","journal-title":"Australas J Dermatol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103177_bib31","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/13685538.2019.1678582","article-title":"Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test?","volume":"23","author":"Ala\u015fan","year":"2021","journal-title":"Aging Male"},{"key":"10.1016\/j.eclinm.2025.103177_bib32","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212598","article-title":"Use of biologic agents and risk of tuberculosis in Brazil, a tuberculosis high-burden country","volume":"9","author":"Chaer","year":"2020","journal-title":"Drugs Context"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103177_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/ard.61.3.251","article-title":"Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment","volume":"61","author":"Gaitonde","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bjd.13130","article-title":"Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy","volume":"171","author":"Gisondi","year":"2014","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103177_bib35","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1128\/CVI.00049-13","article-title":"High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy","volume":"20","author":"He","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.eclinm.2025.103177_bib36","first-page":"1864","article-title":"Screening for latent tuberculosis infection before biologics in algerian patients with rheumatic diseases","volume":"82","author":"Heddi","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103177_bib37","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jmii.2017.04.001","article-title":"Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders - a retrospective cohort study in Taiwan","volume":"51","author":"Huang","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103177_bib38","first-page":"294","article-title":"Completion rate and compliance of anti-tuberculosis chemoprophylaxis in patients with rheumatic disease receiving tumour necrosis factor antagonists","volume":"28","author":"Ideguchi","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103177_bib39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4314\/ahs.v23i2.14","article-title":"Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy","volume":"23","author":"Coskunol","year":"2023","journal-title":"Afr Health Sci"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103177_bib40","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s10067-007-0591-4","article-title":"Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNF alpha","volume":"26","author":"Hanta","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103177_bib41","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1248\/bpb.b23-00521","article-title":"Analysis of risk factors for developing tuberculosis in patients who received prophylactic latent tuberculosis infection treatment with experience of biologic medications","volume":"46","author":"Itagaki","year":"2023","journal-title":"Biol Pharmaceut Bull"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103177_bib42","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.rmed.2013.08.011","article-title":"Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis","volume":"107","author":"Jo","year":"2013","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103177_bib43","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103177_bib44","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00296-015-3249-6","article-title":"Follow-up results of isoniazid chemoprophylaxis during biological therapy in Colombia","volume":"35","author":"Carlos Catano","year":"2015","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103177_bib45","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.5588\/ijtld.12.0004","article-title":"Combined use of a TST and the T-SPOT (R). TB assay for latent tuberculosis infection diagnosis before anti-TNF-alpha treatment","volume":"16","author":"Jung","year":"2012","journal-title":"Int J Tubercul Lung Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib46","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5588\/ijtld.13.0644","article-title":"The 'either test positive' strategy for latent tuberculous infection before anti-tumour necrosis factor treatment","volume":"18","author":"Jung","year":"2014","journal-title":"Int J Tubercul Lung Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103177_bib47","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1513\/AnnalsATS.201608-647OC","article-title":"Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist","volume":"14","author":"Lee","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103177_bib48","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3109\/00365548.2014.938691","article-title":"Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold in Tube assay","volume":"46","author":"Kim","year":"2014","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103177_bib49","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3349\/ymj.2014.55.2.442","article-title":"Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-alpha therapy","volume":"55","author":"Yoo","year":"2014","journal-title":"Yonsei Med J"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153217","article-title":"Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a nationwide retrospective cohort study in taiwan","volume":"11","author":"Liao","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103177_bib51","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"45","key":"10.1016\/j.eclinm.2025.103177_bib52","first-page":"3579","article-title":"Yufang zhiliaoxi tongxing hongban langchuang huanzhe yiyuanxing huodongxing jiehebing de linchuang guancha [Clinical observation of prophylactic treatment of iatrogenic active tuberculosis in patients with systemic lupus erythematosus]","author":"Ma","year":"2014","journal-title":"Zhonghua Yixue Zazhi"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103177_bib53","first-page":"83","article-title":"Risk of latent tuberculosis in the cohort of patients with rheumatoid arthritis in Slovakia","volume":"70","author":"Malinov\u00e1","year":"2021","journal-title":"Epidemiol Mikrobiol Imunol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13913","article-title":"Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: an observational cohort 10-year study from the BIOPURE registry","volume":"53","author":"Fornaro","year":"2023","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103177_bib55","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1080\/09546634.2022.2062280","article-title":"Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection","volume":"33","author":"Megna","year":"2022","journal-title":"J Dermatol Treat"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib56","first-page":"609","article-title":"Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy","volume":"32","author":"Mo","year":"2005","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103177_bib57","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s10067-015-3099-3","article-title":"Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom","volume":"34","author":"Nisar","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.eclinm.2025.103177_bib58","article-title":"Differences in the manegement of latent tuberculosis infection in patients treated with anti-TNF\u03b1 in Turkey","volume":"40","author":"Ocal","year":"2012","journal-title":"Eur Respir J"},{"issue":"19\u201320","key":"10.1016\/j.eclinm.2025.103177_bib59","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00508-013-0417-0","article-title":"Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis","volume":"125","author":"Kurt","year":"2013","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.eclinm.2025.103177_bib60","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/annrheumdis-2024-eular.4376","article-title":"Latent tuberculosis rescreening in spondyloarthritis: how should latent tuberculosis negative patients be followed up?","volume":"83","author":"\u00d6zsoy","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eclinm.2025.103177_bib61","first-page":"1356","article-title":"Isoniazid monotherapy as a prophylaxis for tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids","volume":"70","author":"Park","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103177_bib62","first-page":"47","article-title":"Follow up results of latent tuberculosis infection in patients treated with anti-tnf-alpha","volume":"10","author":"Mutlu","year":"2014","journal-title":"Nobel Medicus"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103177_bib63","first-page":"301","article-title":"Use of an enzyme-linked immunospot assay for diagnosing latent tuberculosis infection in patients with rheumatic diseases","volume":"14","author":"Qiu","year":"2010","journal-title":"Zhonghua Feng Shi Bing Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103177_bib64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejcdt.2014.11.027","article-title":"Tuberculosis chemoprophylaxis in rheumatoid arthritic patients receiving tumor necrosis factor inhibitors or conventional therapy","volume":"64","author":"Samra","year":"2015","journal-title":"Egypt J Chest Dis Tuberc"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib65","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5578\/tt.8452","article-title":"Latent tuberculosis treatment results in patients that taken TNF-alpha blockers at Ankara Numune training and research hospital chest diseases clinic for last 8 years (2006-2013)","volume":"62","author":"Demir","year":"2014","journal-title":"Tuberk Toraks"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103177_bib66","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000434684","article-title":"Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-\u03b1 treatment","volume":"90","author":"Borekci","year":"2015","journal-title":"Respiration"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103177_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14512","article-title":"Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study","volume":"33","author":"Shu","year":"2020","journal-title":"Dermatol Ther"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103177_bib68","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tubercul Lung Dis"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103177_bib69","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2021.36.e70","article-title":"Risk of tuberculosis development in patients with rheumatoid arthritis receiving targeted therapy: a prospective single center cohort study","volume":"36","author":"Song","year":"2021","journal-title":"J Kor Med Sci"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103177_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003946","article-title":"Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis","volume":"10","author":"Song","year":"2024","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103177_bib71","first-page":"679","article-title":"Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong - the role of TNF blockers in an area of high tuberculosis burden","volume":"28","author":"Tam","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib72","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/crj.12726","article-title":"Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: tuberculin skin test conversion and tuberculosis risk","volume":"12","author":"Cagatay","year":"2018","journal-title":"Clin Respir J"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103177_bib73","article-title":"Tuberculin skin test repetition after TNF-\u03b1 inhibitors in patients with chronic inflammatory arthritis: a long-term retrospective cohort in endemic area","volume":"64","author":"Magalhaes","year":"2024","journal-title":"Adv Rheumatol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103177_bib74","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/1756-185X.13376","article-title":"Biologics and risk of tuberculosis in autoimmune rheumatic diseases: a real-world clinical experience from India","volume":"22","author":"Shobha","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103177_bib75","first-page":"906","article-title":"3HP regimen in the treatment of rheumatic diseases complicated with Mycobacterium tuberculosis latent infection; a prospective study","volume":"44","author":"Wang","year":"2022","journal-title":"Chin J Antituberc"},{"issue":"Supplement 2","key":"10.1016\/j.eclinm.2025.103177_bib76","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/annrheumdis-2017-eular.3937","article-title":"Efficacy and safety of prophylactic treatment on activiation of latent tuberculosis during glucocorticoid therapy in patients with rheumatic diseases","volume":"76","author":"Wu","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103177_bib77","first-page":"519","article-title":"Yingyong yiyanjing yufang xitongxing hongban langchuang huanzhe jiehe ganran de zuoyong pinggu [Evaluation of the role of isoniazid in preventing tuberculosis infection in patients with systemic lupus erythematosus]","volume":"39","author":"Xie","year":"2008","journal-title":"Sichuan Daxue Xuebao"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103177_bib78","first-page":"138","article-title":"Yiyanjing dui changqi jieshou jia'an dieqin zhiliao de leifengshi guanjieyan huanzhe jiehe ganran de yufang zuoyong [Preventive effect of isoniazid on tuberculosis infection in patients with rheumatoid arthritis receiving long-term methotrexate treatment]","volume":"40","author":"Xie","year":"2009","journal-title":"Sichuan Daxue Xuebao"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103177_bib79","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1007\/s10067-021-05697-5","article-title":"Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy","volume":"40","author":"Kaptan","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib80","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/23744235.2015.1113436","article-title":"Adequacy of initiating TNF antagonists within 3 weeks of starting latent tuberculosis infection treatment in patients with immune-mediated inflammatory diseases","volume":"48","author":"Yang","year":"2016","journal-title":"Infect Dis"},{"issue":"98","key":"10.1016\/j.eclinm.2025.103177_bib81","first-page":"74","article-title":"Yiyanjing yufang xitongxing hongban langchuang huanzhe jiehe ganran de linchuang fenxi [Clinical analysis of isoniazid prophylaxis for tuberculosis infection in patients with systemic lupus erythematosus]","volume":"15","author":"Zhao","year":"2015","journal-title":"Shijie Zuixin Yixue Xinxi Wenzhai"},{"key":"10.1016\/j.eclinm.2025.103177_bib82","author":"Fengshi","year":"2018"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103177_bib83","first-page":"1294","volume":"44","author":"Zhou","year":"2022","journal-title":"Zhongguo Fang Lao Za Zhi"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103177_bib84","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","article-title":"Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics","volume":"16","author":"Chiu","year":"2020","journal-title":"Expet Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103177_bib85","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccm.2019.07.008","article-title":"Treatment of latent tuberculosis infection-an update","volume":"40","author":"Huaman","year":"2019","journal-title":"Clin Chest Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103177_bib86","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service\/Tuberculosis Research Centre, Madras\/British Medical Research Council","volume":"145","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103177_bib87","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14787210.2018.1483238","article-title":"Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs","volume":"16","author":"Goletti","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103177_bib88","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1183\/09031936.00107608","article-title":"QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases","volume":"33","author":"Bartalesi","year":"2009","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103177_bib89","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1002\/ppul.24963","article-title":"Determination of tuberculin skin test for isoniazid prophylaxis in BCG vaccinated children who are using anti-TNF agents for rheumatologic diseases","volume":"55","author":"Kilinc","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103177_bib90","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon gamma release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103177_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00848-23","article-title":"Latent tuberculosis infection and associated factors in patients with systemic lupus erythematosus: a multicenter, cross-sectional study","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103177_bib92","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12879-023-08008-2","article-title":"Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103177_bib93","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/acr.22591","article-title":"Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines","volume":"67","author":"Tunnicliffe","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.eclinm.2025.103177_bib94","series-title":"Modern epidemiology","author":"KJRSGTL","year":"2008"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103177_bib95","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/aje\/kwaa205","article-title":"Meta-analysis and sparse-data bias","volume":"190","author":"Richardson","year":"2021","journal-title":"Am J Epidemiol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:41:23Z","timestamp":1786135283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025001099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":95,"alternative-id":["S2589537025001099"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103177","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of tuberculosis preventive treatment in patients with rheumatic diseases: a global systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103177"}}